Acute myeloid leukaemia (AML) is characterized by the most prevalent genetic alteration, the type III receptor Fms-like tyrosine kinase 3 (FLT3) mutation, which affects around one-third of AML patients (Kennedy and Smith, 2020). The gene discussed is FLT3; the disease is acute myeloid leukemia.